DLBCL
MCID: DFF005
MIFTS: 56

Diffuse Large B-Cell Lymphoma (DLBCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Diffuse Large B-Cell Lymphoma

MalaCards integrated aliases for Diffuse Large B-Cell Lymphoma:

Name: Diffuse Large B-Cell Lymphoma 12 53 59 15 38 17 72 33
Dlbcl 53 59
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified 72
Large B-Cell Diffuse Lymphoma 75

Characteristics:

Orphanet epidemiological data:

59
diffuse large b-cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (France); Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050745
ICD10 33 C83.3
MESH via Orphanet 45 D016403
ICD10 via Orphanet 34 C83.3
UMLS via Orphanet 73 C0079744
Orphanet 59 ORPHA544
UMLS 72 C0079744 C2699777

Summaries for Diffuse Large B-Cell Lymphoma

NIH Rare Diseases : 53 Diffuse large B-cell lymphoma (DLBCL), a form of non-Hodgkin lymphoma, is the most common blood cancer. Lymphomas occur when cells of the immune system, known as B lymphocytes, grow and multiply uncontrollably. DLBCL occurs mostly in adults and is a fast-growing (aggressive) lymphoma. It can start in the lymph nodes or outside of the lymphatic system in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. Often, the first sign of DLBCL is a painless rapid swelling in the neck, armpit, abdomen, or groin caused by enlarged lymph nodes. For some people, the swelling may be painful. Other symptoms include night sweats, unexplained fevers, and weight loss. Treatment may differ depending on the location of the tumor and the subtype of lymphoma. For those who have advanced DCBCL and have not been treated previously, a combination of chemotherapy and the monoclonal antibody rituximab (Rituxan) (R-CHOP) may be tried.. In addition, as of October 2017, axicabtagene ciloleucel (brand name: Yescarta), a type of gene therapy, has been approved by the United States FDA to treat DCBCL that is not responding to at least two treatment attempts or has returned after being treated before. A stem cell transplant may also be an option if DLBCL returns or relapses.

MalaCards based summary : Diffuse Large B-Cell Lymphoma, also known as dlbcl, is related to burkitt lymphoma and leukemia, acute lymphoblastic. An important gene associated with Diffuse Large B-Cell Lymphoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Decitabine and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Disease Ontology : 12 A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.

Wikipedia : 75 Diffuse large B-cell lymphoma is a cancer of B cells, a type of white blood cell responsible for... more...

Related Diseases for Diffuse Large B-Cell Lymphoma

Diseases related to Diffuse Large B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 733)
# Related Disease Score Top Affiliating Genes
1 burkitt lymphoma 32.1 MIR155 MIR145 MIR143 MIR127
2 leukemia, acute lymphoblastic 31.4 MIR221 MIR21 MIR155
3 leukemia, acute myeloid 31.1 MIR221 MIR21 MIR155 HOTAIR
4 polymyositis 31.0 MIR21 MIR155 MIR127
5 leukemia, chronic lymphocytic 2 31.0 MIR155 MIR145 MIR143
6 psoriasis 30.9 MIR21 MIR10A MIR106A
7 leiomyoma, uterine 30.9 MIR21 MIR150 MIR10A
8 osteogenic sarcoma 30.9 PANDAR HULC HOTAIR
9 dermatomyositis 30.8 MIR221 MIR21 MIR155
10 thyroid cancer, nonmedullary, 1 30.8 MIR221 MIR155 HULC HOTAIR
11 esophageal cancer 30.2 PEG10 MIR21 MIR106A HULC HOTAIR
12 glioblastoma 30.2 MIR221 MIR21 MIR17HG HOTAIR
13 prostate cancer 29.5 MIR221 MIR21 MIR145 MIR143 MIR127 MIR10A
14 bladder cancer 29.5 PANDAR MIR221 MIR21 MIR145 MIR143 MIR127
15 ovarian cancer 29.4 MIR221 MIR21 MIR155 MIR150 MIR145 MIR143
16 gastric cancer 29.3 PANDAR MIR221 MIR21 MIR150 MIR145 MIR143
17 pancreatic cancer 29.3 MIR221 MIR21 MIR155 MIR143 MIR127 MIR10A
18 colorectal cancer 29.1 PANDAR MIR221 MIR21 MIR155 MIR145 MIR143
19 relapsed/refractory diffuse large b-cell lymphoma 13.0
20 primary cutaneous diffuse large b-cell lymphoma, leg type 13.0
21 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 12.9
22 diffuse large b-cell lymphoma of the central nervous system 12.9
23 diffuse large b-cell lymphoma with chronic inflammation 12.9
24 gray zone lymphoma 12.4
25 t-cell/histiocyte rich large b cell lymphoma 12.1
26 reticulosarcoma 12.0
27 follicular lymphoma 12.0
28 primary mediastinal b-cell lymphoma 11.9
29 richter's syndrome 11.9
30 b-cell lymphoma 11.9
31 mediastinal gray zone lymphoma 11.7
32 lymphoma 11.6
33 primary central nervous system lymphoma 11.4
34 plasmablastic lymphoma 11.4
35 primary mediastinal large b-cell lymphoma 11.4
36 intravascular large b-cell lymphoma 11.3
37 lymphoma, hodgkin, classic 11.3
38 lymphoma, non-hodgkin, familial 11.3
39 alk-positive large b-cell lymphoma 11.2
40 neutropenia 11.0
41 lymphocytic leukemia 10.9
42 mantle cell lymphoma 10.9
43 leukemia, chronic lymphocytic 10.9
44 leukemia, b-cell, chronic 10.9
45 lymphoma, mucosa-associated lymphoid type 10.9
46 hematopoietic stem cell transplantation 10.8
47 marginal zone b-cell lymphoma 10.8
48 central nervous system lymphoma 10.8
49 lymphosarcoma 10.8
50 lymphoproliferative syndrome 10.8

Graphical network of the top 20 diseases related to Diffuse Large B-Cell Lymphoma:



Diseases related to Diffuse Large B-Cell Lymphoma

Symptoms & Phenotypes for Diffuse Large B-Cell Lymphoma

Drugs & Therapeutics for Diffuse Large B-Cell Lymphoma

Drugs for Diffuse Large B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
2
Epirubicin Approved Phase 4 56420-45-2 41867
3 Endothelial Growth Factors Phase 4
4
Apatinib Phase 4 811803-05-1
5
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
6
Vinblastine Approved Phase 3 865-21-4 241903 13342
7
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
8
Iodine Approved, Investigational Phase 3 7553-56-2 807
9
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
10
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
11
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
12
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
13
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
14
rituximab Approved Phase 3 174722-31-7 10201696
15
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
16
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
17
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
18
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
19
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
20
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
21
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
22
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
23
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
24
Bevacizumab Approved, Investigational Phase 3 216974-75-3
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
26
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
27
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
28 Alkylating Agents Phase 3
29 Hormones Phase 3
30 Anti-Inflammatory Agents Phase 3
31 glucocorticoids Phase 3
32 Immunologic Factors Phase 3
33 Antibiotics, Antitubercular Phase 3
34 Topoisomerase Inhibitors Phase 3
35 Anti-Bacterial Agents Phase 3
36 Immunosuppressive Agents Phase 3
37 Antineoplastic Agents, Hormonal Phase 3
38 Hormone Antagonists Phase 3
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
40 Antineoplastic Agents, Alkylating Phase 3
41 Iodine-131 anti-B1 antibody Phase 3
42 cadexomer iodine Phase 3
43 Antineoplastic Agents, Phytogenic Phase 3
44 Tubulin Modulators Phase 3
45 Antimitotic Agents Phase 3
46 Antibodies Phase 3
47 Immunoglobulins Phase 3
48 Antibodies, Monoclonal Phase 3
49 Micronutrients Phase 3
50 Trace Elements Phase 3

Interventional clinical trials:

(show top 50) (show all 886)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
3 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
4 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
5 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
6 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
7 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
8 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
9 A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) Unknown status NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
10 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
11 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
12 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
13 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Unknown status NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
14 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
15 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
16 A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
17 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
18 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
19 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
20 Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
21 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
22 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
23 Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1. Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
24 A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01148446 Phase 3 Cyclophosphamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
25 Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma. Completed NCT00144755 Phase 3 Darbepoetin alfa
26 A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Completed NCT00332202 Phase 3 enzastaurin;placebo
27 A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line Completed NCT02268045 Phase 3
28 Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma. Completed NCT01987505 Phase 3 Rituximab
29 A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
30 An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL Completed NCT01459887 Phase 3 CHOP combined with CMAB304;CHOP, CMAB304
31 A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed NCT01197560 Phase 2, Phase 3 Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide
32 Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas Completed NCT00355199 Phase 3 Rituximab-HDS;Rituximab-CHOP
33 Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Etoposide;Cytarabine;Melphalan
34 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
35 A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed NCT01889069 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Doxorubicin;Prednisone;Bendamustine
36 A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
37 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01014208 Phase 3 OFATUMUMAB + DHAP;RITUXIMAB + DHAP
38 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma Completed NCT00491491 Phase 3 ibritumomab tiuxetan
39 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
40 A Rand. Trial Comp Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine, and Prednisone) in Patients With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment Completed NCT00774202 Phase 2, Phase 3 Rituxan, Cyclophosphamide, Vincristine, Prednisone;Higher Dose of Rituximab
41 Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN #0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
42 Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL Completed NCT02787239 Phase 3 HLX01;Rituximab;CHOP
43 Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study Recruiting NCT02777736 Phase 3 Methotrexate
44 Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study Recruiting NCT02428751 Phase 3 Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
45 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™ Recruiting NCT03263026 Phase 3 Enzastaurin Hydrochloride
46 Multicenter, Randomized, Double-blind, Parallel Controlled, Phase III Clinical Study to Compare the Efficacy and Safety of TQB2303 in Conbination With CHOP Regimen (T-CHOP) Versus Rituximab in Combination With CHOP Regimen (R-CHOP) in Previously Untreated Subjects With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL) Recruiting NCT03777085 Phase 3 TQB2303;Rituximab
47 A Multicentre, Randomized Phase III Study of Thalidomide Maintenance Treatment in Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03016000 Phase 3 Thalidomide
48 A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma Recruiting NCT03372837 Phase 3 Rituximab
49 An Randomized, Open-label, Phase III Study Comparing Thalidomide Combined With R-CHOP and R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients Recruiting NCT03318835 Phase 3 Thalidomide combined with R-CHOP;R-CHOP
50 Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation Recruiting NCT03229616 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)

Search NIH Clinical Center for Diffuse Large B-Cell Lymphoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Hyaluronidase (ovine)
Polatuzumab vedotin

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Diffuse Large B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Diffuse Large B-Cell Lymphoma

Anatomical Context for Diffuse Large B-Cell Lymphoma

MalaCards organs/tissues related to Diffuse Large B-Cell Lymphoma:

41
B Cells, T Cells, Bone, Bone Marrow, Breast, Thyroid, Liver

Publications for Diffuse Large B-Cell Lymphoma

Articles related to Diffuse Large B-Cell Lymphoma:

(show top 50) (show all 11756)
# Title Authors PMID Year
1
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. 38 88
19287466 2009
2
MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. 38 88
18537969 2008
3
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. 38 88
18318758 2008
4
MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. 38 88
17487835 2007
5
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. 38 88
16041695 2005
6
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. 38 88
15738415 2005
7
Downregulation of microRNAs-143 and -145 in B-cell malignancies. 88
17892514 2007
8
MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. 88
16675453 2006
9
Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. 38
30885066 2019
10
Pediatric mature B-cell NHL, early referral and supportive care problems in a developing country. 38
30149780 2019
11
Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma. 38
31072235 2019
12
Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma. 38
30198830 2019
13
Immunoglobulin D (IgD) and IgD receptor expression in diffuse large B-cell lymphoma. 38
31315540 2019
14
Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma. 38
30101679 2019
15
Retracted article: Adjuvant radiotherapy in patients with diffuse large B-cell lymphoma in advanced stage (III/IV) improves the outcome in the rituximab era. 38
29338665 2019
16
Primary intestinal aspergillosis resulting in acute intestinal volvulus after autologous stem cell transplantation in a patient with relapsed non-Hodgkin lymphoma: report on a rare infectious complication and a review of the literature. 38
30238855 2019
17
Differentiation between sinonasal natural killer/T-cell lymphomas and diffuse large B-cell lymphomas by RESOLVE DWI combined with conventional MRI. 38
31212002 2019
18
Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma. 38
31346688 2019
19
Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients. 38
31228077 2019
20
Clinicopathological characteristics of diffuse large B-cell lymphoma involving small and large intestines: an analysis of 126 patients. 38
31187439 2019
21
Marek's Disease Virus-Encoded MicroRNA 155 Ortholog Critical for the Induction of Lymphomas Is Not Essential for the Proliferation of Transformed Cell Lines. 38
31189706 2019
22
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. 38
30045683 2019
23
Challenges in the Diagnosis of Gray Zone Lymphomas. 38
31352983 2019
24
Diagnosis and management of follicular lymphoma: A comprehensive review. 38
31270855 2019
25
Significance of biopsy with ERCP for diagnosis of bile duct invasion of DLBCL. 38
31093933 2019
26
Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. 38
31402495 2019
27
Approaches for vulnerable and frail older patients with diffuse large B-cell lymphomas. 38
31335827 2019
28
Surgical management of primary colonic lymphoma: Big data for a rare problem. 38
31187517 2019
29
Improved clonality analysis based on immunoglobulin kappa locus for canine cutaneous plasmacytoma. 38
31420067 2019
30
Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma. 38
30858144 2019
31
A Rapidly Developing Diffuse Large B cell Lymphoma of the Stomach. 38
29623599 2019
32
Diffuse Large B-Cell Lymphoma With Clear Cell Morphology. 38
30482078 2019
33
Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma. 38
31352982 2019
34
Pediatric Diffuse Large B-Cell Lymphoma of the Frontal Sinus: A Case Report. 38
30836788 2019
35
Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms. 38
30467669 2019
36
Concurrent Diffuse Large B-Cell Lymphoma and Epstein-Barr Virus-Associated Smooth Muscle Tumour in the Small Bowel of an HIV-Positive Adult-a Case Report and Review of the Literature. 38
29297137 2019
37
Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy. 38
31189540 2019
38
Primary central nervous system lymphoma: Novel precision therapies. 38
31295667 2019
39
Clinical characteristics and outcomes of primary adrenal diffuse large B cell lymphoma in a large contemporary cohort: a SEER-based analysis. 38
31227873 2019
40
Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome. 38
30664812 2019
41
The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. 38
31211907 2019
42
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. 38
31385336 2019
43
Computer analysis of histopathological images for tumor grading. 2. 38
31158821 2019
44
Diagnostic Performance of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/CT for Chronic Empyema-Associated Malignancy. 38
31339017 2019
45
BCL6 inhibitor FX1 attenuates inflammatory responses in murine sepsis through strengthening BCL6 binding affinity to downstream target gene promoters. 38
31401377 2019
46
Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma. 38
31427235 2019
47
Soluble CXCL16 promotes TNF-α-induced apoptosis in DLBCL via the AMAD10-NF-κB regulatory feedback loop. 38
31033093 2019
48
Rituximab in Primary Central Nervous System Lymphoma - A Systematic Review and Meta-analysis. 38
31418878 2019
49
Comprehensive analysis of the influence of G-CSF on the biodistribution of 18F-FDG in lymphoma patients: insights for PET/CT scheduling. 38
31432277 2019
50
Case 272. 38
31318656 2019

Variations for Diffuse Large B-Cell Lymphoma

Cosmic variations for Diffuse Large B-Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM37032 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,diffuse large B cell lymphoma c.1937A>G p.Y646C 7:148811635-148811635 0

Copy number variations for Diffuse Large B-Cell Lymphoma from CNVD:

7 (show top 50) (show all 118)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13828 1 1 84900000 Loss Diffuse large b-cell lymphoma
2 17406 1 142600000 249250621 Gain Diffuse large b-cell lymphoma
3 20082 1 15300000 163800000 Gain Diffuse large b-cell lymphoma
4 38345 10 101900000 103000000 Gain Diffuse large b-cell lymphoma
5 38773 10 104900000 105800000 Gain Diffuse large b-cell lymphoma
6 38901 10 105800000 121700000 Loss Diffuse large b-cell lymphoma
7 40597 10 130600000 135534747 Loss Diffuse large b-cell lymphoma
8 43294 10 46100000 64500000 Loss Diffuse large b-cell lymphoma
9 48479 11 1 43500000 Gain Diffuse large b-cell lymphoma
10 51204 11 123900000 135006516 Loss Diffuse large b-cell lymphoma
11 53206 11 26100000 36400000 Loss Diffuse large b-cell lymphoma
12 55792 11 55700000 135006516 Gain Diffuse large b-cell lymphoma
13 64291 12 12600000 14800000 Gain CDKN1B Diffuse large b-cell lymphoma
14 70914 12 66000000 69800000 Gain MDM2 Diffuse large b-cell lymphoma
15 74343 13 104800000 110300000 Loss Diffuse large b-cell lymphoma
16 74383 13 105800000 109100000 Loss Diffuse large b-cell lymphoma
17 75387 13 19500000 55300000 Gain Diffuse large b-cell lymphoma
18 76712 13 35500000 75400000 Loss Diffuse large b-cell lymphoma
19 79280 13 68600000 115169878 Gain Diffuse large b-cell lymphoma
20 86223 14 55800000 61200000 Loss Diffuse large b-cell lymphoma
21 88116 14 84900000 107349540 Loss Diffuse large b-cell lymphoma
22 90236 15 20700000 102531392 Loss Diffuse large b-cell lymphoma
23 97251 16 1 34600000 Gain Diffuse large b-cell lymphoma
24 97373 16 1 7900000 Gain ABCA3 Diffuse large b-cell lymphoma
25 97375 16 1 7900000 Gain DCI Diffuse large b-cell lymphoma
26 97377 16 1 7900000 Gain E4F1 Diffuse large b-cell lymphoma
27 97379 16 1 7900000 Gain HAGH Diffuse large b-cell lymphoma
28 97381 16 1 7900000 Gain IGFALS Diffuse large b-cell lymphoma
29 97383 16 1 7900000 Gain MRPS34 Diffuse large b-cell lymphoma
30 97385 16 1 7900000 Gain NME3 Diffuse large b-cell lymphoma
31 97387 16 1 7900000 Gain NUBP2 Diffuse large b-cell lymphoma
32 97391 16 1 7900000 Gain RNPS1 Diffuse large b-cell lymphoma
33 99692 16 28100000 36600000 Loss Diffuse large b-cell lymphoma
34 102840 16 57400000 90354753 Gain Diffuse large b-cell lymphoma
35 102843 16 57400000 90354753 Loss Diffuse large b-cell lymphoma
36 104071 16 66700000 70800000 Gain DDX19 Diffuse large b-cell lymphoma
37 104073 16 66700000 70800000 Gain FUK Diffuse large b-cell lymphoma
38 104075 16 66700000 70800000 Gain SIAT4B Diffuse large b-cell lymphoma
39 106530 16 88700000 90354753 Gain Diffuse large b-cell lymphoma
40 106806 17 1 22200000 Loss Diffuse large b-cell lymphoma
41 111431 17 3600000 6800000 Loss TP53 Diffuse large b-cell lymphoma
42 120634 18 2900000 78077248 Gain Diffuse large b-cell lymphoma
43 121454 18 43500000 48200000 Gain Diffuse large b-cell lymphoma
44 121719 18 46400000 52000000 Gain BCL2 Diffuse large b-cell lymphoma
45 122173 18 53800000 56200000 Gain MALT1 Diffuse large b-cell lymphoma
46 123098 18 66800000 68700000 Loss Diffuse large b-cell lymphoma
47 123108 18 66900000 71300000 Gain Diffuse large b-cell lymphoma
48 127687 19 35500000 38300000 Gain KIRREL2 Diffuse large b-cell lymphoma
49 127689 19 35500000 38300000 Gain MLL4 Diffuse large b-cell lymphoma
50 127691 19 35500000 38300000 Gain NPHS1 Diffuse large b-cell lymphoma

Expression for Diffuse Large B-Cell Lymphoma

Search GEO for disease gene expression data for Diffuse Large B-Cell Lymphoma.

Pathways for Diffuse Large B-Cell Lymphoma

Pathways related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.72 MIR221 MIR21 MIR17 MIR155 MIR150 MIR145
2 11.28 MIR17HG MIR17 MIR127 MIR10A MIR106A

GO Terms for Diffuse Large B-Cell Lymphoma

Cellular components related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 MIR221 MIR21 MIR17 MIR155 MIR150 MIR143

Biological processes related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.8 MIR221 MIR21 MIR143
2 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.65 MIR221 MIR21 MIR17
3 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.64 MIR21 MIR145
4 negative regulation of sprouting angiogenesis GO:1903671 9.64 MIR221 MIR17
5 activation of protein kinase B activity GO:0032148 9.63 MIR21 MIR143
6 negative regulation of smooth muscle cell proliferation GO:0048662 9.62 MIR145 MIR143
7 positive regulation of activated T cell proliferation GO:0042104 9.62 MIR21 MIR155
8 negative regulation of angiogenesis GO:0016525 9.62 MIR21 MIR145 MIR143 MIR10A
9 positive regulation of cardiac muscle hypertrophy GO:0010613 9.61 MIR21 MIR155
10 regulation of smooth muscle contraction GO:0006940 9.61 MIR145 MIR143
11 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.6 MIR221 MIR155
12 negative regulation of cardiac muscle hypertrophy GO:0010614 9.59 MIR21 MIR145
13 positive regulation of endothelial cell differentiation GO:0045603 9.58 MIR21 MIR150
14 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.58 MIR21 MIR17
15 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.57 MIR17 MIR155
16 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.56 MIR17 MIR155
17 positive regulation of metalloendopeptidase activity GO:1904685 9.55 MIR21 MIR17
18 angiotensin-activated signaling pathway GO:0038166 9.54 MIR145 MIR143
19 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.52 MIR21 MIR17
20 negative regulation of regulatory T cell differentiation GO:0045590 9.51 MIR21 MIR155
21 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.49 MIR221 MIR155
22 aorta smooth muscle tissue morphogenesis GO:0060414 9.46 MIR145 MIR143
23 regulation of phenotypic switching GO:1900239 9.43 MIR145 MIR143
24 miRNA mediated inhibition of translation GO:0035278 9.43 MIR221 MIR21 MIR17 MIR155 MIR145 MIR106A
25 negative regulation of cell adhesion molecule production GO:0060354 9.4 MIR221 MIR155
26 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.37 MIR17 MIR143
27 gene silencing by miRNA GO:0035195 9.36 MIR221 MIR21 MIR17HG MIR17 MIR155 MIR150
28 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.33 MIR221 MIR21 MIR143
29 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.26 MIR145 MIR143

Molecular functions related to Diffuse Large B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR221 MIR21 MIR17HG MIR17 MIR155 MIR150

Sources for Diffuse Large B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....